These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 7831345)

  • 1. Tamoxifen experimental carcinogenicity studies: implications for human effects.
    Williams GM
    Proc Soc Exp Biol Med; 1995 Feb; 208(2):141-3. PubMed ID: 7831345
    [No Abstract]   [Full Text] [Related]  

  • 2. The tamoxifen controversy--clinical chemopreventive agent and experimental carcinogen.
    Pitot HC
    Proc Soc Exp Biol Med; 1995 Feb; 208(2):139-40. PubMed ID: 7831344
    [No Abstract]   [Full Text] [Related]  

  • 3. The metabolism and genotoxicity of tamoxifen.
    White IN; Martin EA; Styles J; Lim CK; Carthew P; Smith LL
    Prog Clin Biol Res; 1997; 396():257-70. PubMed ID: 9108603
    [No Abstract]   [Full Text] [Related]  

  • 4. Cumulative exposure to tamoxifen: DNA adducts and liver cancer in the rat.
    Carthew P; Lee PN; Edwards RE; Heydon RT; Nolan BM; Martin EA
    Arch Toxicol; 2001 Aug; 75(6):375-80. PubMed ID: 11570696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adducts and tamoxifen.
    Busch H
    Semin Oncol; 1997 Feb; 24(1 Suppl 1):S1-98-S1-104. PubMed ID: 9045322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of tumors with DNA adducts from methyl eugenol and tamoxifen in rats.
    Waddell WJ; Crooks NH; Carmichael PL
    Toxicol Sci; 2004 May; 79(1):38-40. PubMed ID: 14976343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should clinicians be concerned about the carcinogenic potential of tamoxifen?
    Jordan VC; Morrow M
    Eur J Cancer; 1994; 30A(11):1714-21. PubMed ID: 7833150
    [No Abstract]   [Full Text] [Related]  

  • 8. Animal tests take back seat to clinical data.
    Seachrist L
    Science; 1994 Jun; 264(5165):1525. PubMed ID: 8202703
    [No Abstract]   [Full Text] [Related]  

  • 9. Understanding the genotoxicity of tamoxifen?
    Phillips DH
    Carcinogenesis; 2001 Jun; 22(6):839-49. PubMed ID: 11375888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delayed effects of tamoxifen in hepatocarcinogenesis-resistant Fischer 344 rats as compared with susceptible strains.
    Stanley LA; Carthew P; Davies R; Higginson F; Martin E; Styles JA
    Cancer Lett; 2001 Sep; 171(1):27-35. PubMed ID: 11485825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genotoxic effects of the novel mixed antiestrogen FC-1271a in comparison to tamoxifen and toremifene.
    Hellmann-Blumberg U; Taras TL; Wurz GT; DeGregorio MW
    Breast Cancer Res Treat; 2000 Mar; 60(1):63-70. PubMed ID: 10845810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tamoxifen for breast cancer prevention.
    Jordan VC
    Proc Soc Exp Biol Med; 1995 Feb; 208(2):144-9. PubMed ID: 7831346
    [No Abstract]   [Full Text] [Related]  

  • 13. Major inter-species differences in the rates of O-sulphonation and O-glucuronylation of alpha-hydroxytamoxifen in vitro: a metabolic disparity protecting human liver from the formation of tamoxifen-DNA adducts.
    Boocock DJ; Maggs JL; Brown K; White IN; Park BK
    Carcinogenesis; 2000 Oct; 21(10):1851-8. PubMed ID: 11023543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemoprevention of breast cancer by tamoxifen: risks and opportunities.
    Smith LL; Brown K; Carthew P; Lim CK; Martin EA; Styles J; White IN
    Crit Rev Toxicol; 2000 Sep; 30(5):571-94. PubMed ID: 11055836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA adducts caused by tamoxifen and toremifene in human microsomal system and lymphocytes in vitro.
    Hemminki K; Widlak P; Hou SM
    Carcinogenesis; 1995 Jul; 16(7):1661-4. PubMed ID: 7614704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pyrrolizidine alkaloid-derived DNA adducts as a common biological biomarker of pyrrolizidine alkaloid-induced tumorigenicity.
    Xia Q; Zhao Y; Von Tungeln LS; Doerge DR; Lin G; Cai L; Fu PP
    Chem Res Toxicol; 2013 Sep; 26(9):1384-96. PubMed ID: 23937665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats.
    Hard GC; Iatropoulos MJ; Jordan K; Radi L; Kaltenberg OP; Imondi AR; Williams GM
    Cancer Res; 1993 Oct; 53(19):4534-41. PubMed ID: 8402624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients.
    Hemminki K; Rajaniemi H; Lindahl B; Moberger B
    Cancer Res; 1996 Oct; 56(19):4374-7. PubMed ID: 8813128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formation and repair of DNA adducts in vinyl chloride- and vinyl fluoride-induced carcinogenesis.
    Swenberg JA; Bogdanffy MS; Ham A; Holt S; Kim A; Morinello EJ; Ranasinghe A; Scheller N; Upton PB
    IARC Sci Publ; 1999; (150):29-43. PubMed ID: 10626206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies of tamoxifen as a promoter of hepatocarcinogenesis in female Fischer F344 rats.
    Dragan YP; Fahey S; Street K; Vaughan J; Jordan VC; Pitot HC
    Breast Cancer Res Treat; 1994; 31(1):11-25. PubMed ID: 7981451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.